跳至主要内容
临床试验/NCT02644083
NCT02644083终止不适用

Modulation of Cerebral Grey Matter High Energy Phosphate Metabolites in Multiple Sclerosis by Dimethyl Fumarate

Oregon Health and Science University1 个研究点 分布在 1 个国家目标入组 4 人开始时间: 2016年2月最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
终止
入组人数
4
试验地点
1
主要终点
Changes in phosphocreatine (PCr) in cerebral grey matter

研究概览

简要总结

The primary objective of this study is to test the hypothesis that DMF can improve mitochondrial function in the brain of people with MS. The investigators will assess mitochondrial function in the cerebral grey matter by measuring PCr and ATP by 31P magnetic resonance spectroscopy (MRS) and NAA in NAWM by 1H MRS.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 55 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosis of MS by 2010 McDonald criteria
  • Relapsing clinical course
  • Ages 18-55
  • Laboratory values that allow initiation of dimethyl fumarate (Tecfidera)

排除标准

  • Systemic disease associated with cerebrovascular disease (e.g. diabetes mellitus, hypertension, hyperlipidemia, coronary heart disease)
  • Treatment with corticosteroids or disease-modifying therapies (interferon beta, glatiramer acetate, natalizumab, fingolimod, teriflunomide) within 30 days of the first baseline MRI scan.
  • Treatment at any time with mitoxantrone, cyclophosphamide, or any other long acting immunosuppressant
  • Prior treatment of greater than 1 month at any time with DMF
  • Inability to tolerate MRI procedures
  • Pregnant/breastfeeding

结局指标

主要结局

Changes in phosphocreatine (PCr) in cerebral grey matter

时间窗: baseline and 6 months of treatment with Dimethyl Fumarate (DMF)

PCr levels evaluated by magnetic resonance spectroscopy

次要结局

  • Changes in ATP in normal appearing white matter (NAWM)(baseline and 6 months of treatment with Dimethyl Fumarate)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Rebecca Spain

Dr Rebecca Spain, MD, MSPH

Oregon Health and Science University

研究点 (1)

Loading locations...

相似试验